INDIGO Biosciences launches human 5-HT2A reporter assay for neuroscience drug discovery
INDIGO Biosciences has added a human serotonin 2A receptor reporter assay to its cell-based portfolio for neuropsychiatric drug discovery. The new kit is designed to help researchers test serotonergic therapeutics and generate functional receptor data faster without building an internal assay.
Why it matters: - The human 5-HT2A receptor is a key target in neuropsychiatric drug development. - Functional testing of this receptor supports work in schizophrenia, psychosis, major depressive disorder and substance use disorders. - A standardized assay can shorten setup time and reduce internal assay development work for drug discovery teams.
What happened: - INDIGO Biosciences announced the availability of its Human Serotonin 2A Receptor (5-HT2A) Reporter Assay on Oct. 22, 2026. - The new product expands INDIGO Biosciences’ portfolio of functional assays for neuropsychiatric drug discovery, serotonergic pharmacology and secondary pharmacology screening. - The company said the assay is designed for programs focused on neuropsychiatric therapeutics, psychedelic drug development, serotonergic pharmacology and secondary pharmacology.
The details: - The assay kit includes 5-HT2A reporter cells, optimized media, serotonin as a reference agonist, luciferase detection reagents and a cell culture-ready 96-well plate. - The kit is intended to provide a ready-to-use method for measuring functional receptor activity. - INDIGO Biosciences said the product can help research teams generate reproducible functional data within existing drug discovery workflows. - The company said the assay removes the need to develop, transfect and optimize an internal reporter system.
Between the lines: - Interest in 5-HT2A has broadened as researchers study serotonergic psychedelics and new approaches to psychiatric treatment. - The launch positions INDIGO Biosciences in a research area where functional receptor characterization is becoming more important for candidate evaluation. - The product fits into a broader push among pharmaceutical and biotechnology companies to use cell-based tools earlier in therapeutic development.
What's next: - INDIGO Biosciences is likely to market the assay to teams working on next-generation neuropsychiatric and serotonergic therapies. - Broader use could come from drug discovery programs that need standardized secondary pharmacology data on 5-HT2A activity. - The launch may support further expansion of the company’s cell-based assay lineup in neuroscience and related therapeutic areas.
The bottom line: - INDIGO Biosciences is betting that a turnkey 5-HT2A assay will save time for drug developers while meeting growing demand for serotonergic and neuropsychiatric screening tools.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Harrisburg Daily Digest
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.